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experimental group and 96 in the control group. In the experimental group, the mean age was 38.6 years, 47.4% were men, and there had been 5.4 admissions during the preceding 6.5 years. In the control group, the mean age was 39.8 years, 58.3% were men, and there had been 5.6 admissions during the preceding 6.5 years.
Study design
This was a randomised controlled trial with a parallel design carried out in the area of Brent. Randomisation was performed using random numbers generated by a computer programme. The patients were assessed at baseline by interviewers blinded to the treatment allocation. The patients were then followed for two years. They were assessed after one year and at the end of the follow-up period, during which time the interviewers were aware of patient allocation to the study groups. At the final assessment, 63 patients in the experimental group and 62 in the control group were available for the analysis.
Analysis of effectiveness
The basis of the effectiveness analysis was intention to treat. The primary health outcomes assessed in the analysis were:
the Health of the National Outcome Scale (HoNOS), where a maximum value of 48 indicated severe dysfunction; the Krawiecka score, where a maximum value of 36 indicated severe dysfunction; the Hospital Anxiety and Depression Scale for both depression and anxiety (HAD-S; maximum value 21), where a value equal or greater than 8 indicated significant dysfunction; the Social Functioning Questionnaire (maximum value 24), where a value equal or greater than 10 indicated significant dysfunction;
the Well-Being Questionnaire, where a maximum value of 30 indicated a high quality of life; the Camberwell Assessment of Need (CAN-user, maximum number of needs 22); and the Ratings of Medication Influences (ROMI) for compliance or non-compliance, where a maximum value of 3 indicated high compliance or high non-compliance.
The study groups were shown to be comparable at baseline in terms of socio-demographic factors.
Effectiveness results
The scores for the outcomes assessed in the analysis changed from baseline to the two-year follow-up.
In particular, the HoNOS changed from 11.36 to 11.9 in the study group and from 12.2 to 10.4 in the control group.
The Krawiecka score changed from 9.6 to 9.2 in the study group and from 8 to 7.9 in the control group.
The HAD-S for depression changed from 7.4 to 7.3 in the study group and from 6.4 to 6.8 in the control group.
The HAD-S for anxiety changed from 7.3 to 7.5 in the study group and from 5.8 to 6.4 in the control group.
The Social Functioning Questionnaire score changed from 8.4 to 8.9 in the study group and from 7.8 to 7.9 in the control group.
The Well-Being Questionnaire changed from 15.8 to 13.4 in the study group and from 16.1 to 14.9 in the control group.
The CAN-user changed from 7.7 to 6.6 in the study group and from 7.9 to 5.6 in the control group.
The ROMI compliance score was 1.8 at both the one-year and two-year assessment in the study group. The corresponding scores in the control group were 2 (one-year assessment) and 1.9 (two-year assessment).
The ROMI non-compliance score was 1.3 at the one-year assessment and 1.2 at the two-year assessment in the study group. The corresponding scores in the control group were both 1.2.
None of the differences between the study groups reached statistical significance.
Clinical conclusions
The effectiveness analysis showed that there was no statistically significant difference in any of the outcome measures estimated.
Measure of benefits used in the economic analysis
No statistically significant difference was found in any of the outcome measures assessed in the effectiveness analysis, thus a cost-minimisation analysis was conducted.
Direct costs
Discounting was not conducted since the costs were incurred over two years. The unit costs and the quantities of resources were not reported. The health service costs included in the economic evaluation were inpatient costs, dayhospital costs, outpatient costs and community team costs. The cost/resource boundary adopted was not stated, but appears to have been that of the local hospital. The quantities were estimated from the trial, while the unit costs were primarily obtained from local account data. When local data were unavailable, national published cost data were used. The pharmacy costs were not included in the analysis. The costs were estimated in 1995 to 1996 prices.
Statistical analysis of costs
Standard statistical analyses of the costs were conducted to assess the statistical significance of the results.
Indirect Costs
The indirect costs were not included in the analysis. However, the authors stated that the indirect costs were estimated to be approximately 15% of the total costs.
Currency

UK pounds sterling ().
Sensitivity analysis
No sensitivity analyses were carried out.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total costs for the intervention group were 7,928 at baseline, 8,310 at the one-year follow-up and 6,968 at the twoyear follow-up. The total costs for the control group were 8,392 at baseline, 7,868 at the one-year follow-up and 7,316 at the two-year follow-up. The difference was not found to be statistically significant. However, the outpatient costs decreased significantly faster in the control group than in the intervention group.
In terms of resource use, no difference between the groups was found in terms of occupied bed days, day-hospital appointments attended and outpatient appointments attended. However, face-to-face contacts and non-face-to-face contacts by community teams were significantly more in the intervention group than in the control group.
